Amgen to Build Generative AI Models for Novel Human Data Insights and Drug Discovery
NVIDIA: Healthcare
JANUARY 8, 2024
Generative AI is transforming drug research and development, enabling new discoveries faster than ever — and Amgen, one of the world’s leading biotechnology companies, is tapping the technology to power its research. Amgen will build AI models trained to analyze one of the world’s largest human datasets on an NVIDIA DGX SuperPOD , a full-stack data center platform, that will be installed at Amgen’s deCODE genetics’ headquarters in Reykjavik, Iceland.
Let's personalize your content